Promising Nanotechnology Stocks To Research – March 29th

OSI Systems, NVE, Virpax Pharmaceuticals, Biodexa Pharmaceuticals, Clene, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks represent shares in companies that develop or employ technologies operating at the nanoscale, which is roughly one to 100 nanometers. They often involve innovative research and applications in fields like medicine, electronics, energy, and materials science, positioning these companies at the forefront of next-generation technological advancements. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

NASDAQ:OSIS traded down $5.79 during mid-day trading on Friday, hitting $193.32. 172,142 shares of the company traded hands, compared to its average volume of 175,453. The company has a quick ratio of 1.25, a current ratio of 1.88 and a debt-to-equity ratio of 0.56. The stock’s fifty day moving average price is $196.64 and its 200-day moving average price is $170.88. The firm has a market cap of $3.25 billion, a price-to-earnings ratio of 24.88, a price-to-earnings-growth ratio of 1.81 and a beta of 1.20. OSI Systems has a one year low of $126.57 and a one year high of $220.00.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVE stock traded down $2.09 during midday trading on Friday, hitting $64.99. The stock had a trading volume of 12,878 shares, compared to its average volume of 21,115. NVE has a 52-week low of $63.65 and a 52-week high of $89.98. The company has a market capitalization of $314.36 million, a PE ratio of 20.96 and a beta of 1.08. The firm’s fifty day moving average is $70.06 and its two-hundred day moving average is $75.81.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Shares of VRPX stock traded down $0.14 on Friday, hitting $1.34. 150,930 shares of the stock traded hands, compared to its average volume of 180,118. Virpax Pharmaceuticals has a 52 week low of $1.26 and a 52 week high of $106.75. The firm has a 50 day simple moving average of $5.65 and a two-hundred day simple moving average of $10.77.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of Biodexa Pharmaceuticals stock traded down $0.06 during trading hours on Friday, hitting $1.23. The company’s stock had a trading volume of 81,220 shares, compared to its average volume of 500,861. The stock has a 50 day moving average price of $3.39. Biodexa Pharmaceuticals has a 12-month low of $1.23 and a 12-month high of $74.00.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNN stock traded up $0.04 during midday trading on Friday, hitting $3.22. The company’s stock had a trading volume of 28,570 shares, compared to its average volume of 78,234. Clene has a 12 month low of $3.09 and a 12 month high of $9.20. The company has a 50 day moving average of $4.43 and a two-hundred day moving average of $4.85. The firm has a market capitalization of $26.81 million, a price-to-earnings ratio of -0.61 and a beta of 0.27.

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNNW remained flat at $0.03 during trading on Friday. 1 shares of the company traded hands, compared to its average volume of 14,500. The stock has a 50-day moving average price of $0.04 and a 200-day moving average price of $0.04. Clene has a 52 week low of $0.02 and a 52 week high of $0.08.